BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
4/12/2023 8:10:41 AM | Browse: 164 | Download: 555
 |
Received |
|
2022-10-26 08:28 |
|
Peer-Review Started |
|
2022-10-26 08:31 |
 |
To Make the First Decision |
|
|
|
Return for Revision |
|
2022-12-14 02:39 |
|
Revised |
|
2022-12-16 08:33 |
|
Second Decision |
|
2023-03-23 03:15 |
|
Accepted by Journal Editor-in-Chief |
|
|
|
Accepted by Company Editor-in-Chief |
|
2023-03-23 09:45 |
|
Articles in Press |
|
2023-03-23 09:45 |
|
Publication Fee Transferred |
|
|
|
Edit the Manuscript by Language Editor |
|
2023-03-02 08:22 |
|
Typeset the Manuscript |
|
2023-03-27 08:10 |
|
Publish the Manuscript Online |
|
2023-04-12 08:10 |
| ISSN |
1948-5204 (online) |
| Open Access |
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/ |
| Copyright |
© The Author(s) 2023. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Gastroenterology & Hepatology |
| Manuscript Type |
Retrospective Study |
| Article Title |
Correlation between immune-related adverse events and long-term outcomes in pembrolizumab-treated patients with unresectable hepatocellular carcinoma: A retrospective study
|
| Manuscript Source |
Unsolicited Manuscript |
| All Author List |
Jiang-Min Zhou, Hui-Fang Xiong, Xiao-Ping Chen, Zhi-Wei Zhang, Li-Ping Zhu and Biao Wu |
| ORCID |
|
| Funding Agency and Grant Number |
|
| Corresponding Author |
Biao Wu, MD, Doctor, Department of Hepatobiliary Surgery, Wuhan Hospital of Traditional Chinese and Western Medicine, No. 215 Zhongshan Avenue, Qiaokou District, Wuhan 430030, Hubei Province, China. wuhanyywb@163.com |
| Key Words |
Hepatocellular carcinoma; Immune checkpoint inhibitors; Pembrolizumab; Immune-related adverse events; Overall survival; Retrospective study |
| Core Tip |
This is a retrospective study to elucidate the correlation between immune-related toxic effects and prognosis in patients with unresectable hepatocellular carcinoma (HCC) treated with pembrolizumab. One hundred and forty-three male patients and forty-seven female patients were included in the study. The overall incidence of treatment-related adverse events was 72.6% (138/190) and 10.0% of them were severe immune-related adverse events (irAEs) (grade ≥ 3). Patients with hypothyroidism were observed to have a longer overall survival and time to progression than those without irAEs. Unresectable HCC patients who experienced hypothyroidism had a better therapeutic effect. |
| Publish Date |
2023-04-12 08:10 |
| Citation |
Zhou JM, Xiong HF, Chen XP, Zhang ZW, Zhu LP, Wu B. Correlation between immune-related adverse events and long-term outcomes in pembrolizumab-treated patients with unresectable hepatocellular carcinoma: A retrospective study. World J Gastrointest Oncol 2023; 15(4): 689-699 |
| URL |
https://www.wjgnet.com/1948-5204/full/v15/i4/689.htm |
| DOI |
https://dx.doi.org/10.4251/wjgo.v15.i4.689 |
© 2004-2024 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
California Corporate Number: 3537345
